Kabazitaksel Ever Pharma (Cabazitaxel)

Cabazitaxel is a taxane chemotherapy used in the management of advanced prostate cancer that has progressed despite prior therapy.

• Metastatic castration‑resistant prostate cancer after docetaxel: extends overall survival in patients with disease progression.
• Advanced prostate cancer with taxane resistance: provides an alternative chemotherapy option.
• Prostate adenocarcinoma refractory to first‑line treatment: offers clinical benefit in later‑line settings.

• Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerization and stabilizing the microtubule network. This prevents depolymerization, disrupts mitotic spindle formation, arrests cells in the G2/M phase, and ultimately triggers apoptosis of rapidly dividing cancer cells, particularly those resistant to other taxanes.

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea and vomiting: gastrointestinal upset common during treatment.
• Diarrhea: loose stools that may require supportive care.
• Alopecia: hair loss that is usually reversible.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Pulmonary toxicity: shortness of breath or interstitial lung disease.
• Cardiac arrhythmias: irregular heart rhythms observed in some patients.
• Life‑threatening infections: sepsis due to immunosuppression.
• Death: rare but reported in heavily pre‑treated populations.

Before initiating Cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications.

• Hematologic monitoring: perform complete blood counts before each cycle to detect neutropenia.
• Hepatic function: evaluate liver enzymes as cabazitaxel is metabolized hepatically.
• Infection risk: avoid use in patients with active severe infections.
• Contraception: advise both male and female patients of reproductive potential to use effective contraception during treatment and for a defined period after.
• Cardiac assessment: consider baseline ECG in patients with known cardiac disease.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Cabazitaxel can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure and toxicity.
• Concurrent myelosuppressive agents (e.g., other chemotherapy, high‑dose steroids): heighten risk of severe neutropenia.
• Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels, lowering effectiveness.
• Anticoagulants (e.g., warfarin, DOACs): monitor for bleeding as platelet counts may fall.
• Diuretics: watch electrolyte balance, especially if renal function is impaired.